Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab + RVD in Newly Diagnosed Multiple Myeloma
NCT01531998Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2012
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of siltuximab in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Started May 2012; status: completed.
02
Drugs
siltuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01531998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01531998.